Request for clarification from Ruiter et al regarding ‘Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study’. Reply to Carstensen B [letter]

Ítems similars

• Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study
  per: Ruiter, R., et al.
  Publicat: (2011)
• Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin
  per: Stürmer, Til, et al.
  Publicat: (2013)
• Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements
  per: Pearson, Scott M., et al.
  Publicat: (2018)
• Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue
  per: Werner, Ulrich, et al.
  Publicat: (2014)
• Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
  per: Hartmann, Thorsten, et al.
  Publicat: (2016)